# Cardiac biomarkers, intensive blood pressure treatment and risk of adverse cardiovascular outcomes in type 2 diabetes, a secondary analysis of the ACCORD BP

> **NIH NIH R21** · UT SOUTHWESTERN MEDICAL CENTER · 2024 · $124,885

## Abstract

Project Summary
Blood pressure (BP) control is an effective preventive intervention to reduce the risk of cardiovascular disease,
especially heart failure (HF). However, among adults with type 2 diabetes (T2D), the effects of intensive BP
control for HF prevention are not well established. There may be high-risk individuals with T2D who are more
likely to derive greater benefits from intensive BP control. The American Diabetes Association recommends
measurement of cardiac biomarkers, specifically N-terminal pro-B-type natriuretic peptide (NT-proBNP) and
high-sensitivity cardiac troponin T (hs-cTnT), to identify and target individuals at high risk for developing HF
with effective therapies as part of a comprehensive HF prevention strategy. In this study, we propose to
evaluate whether a cardiac biomarker-based approach can inform intensive BP control treatment decisions in
high-risk adults with T2D to prevent HF. The study will examine participants enrolled in the ACCORD-BP trial
with available biospecimens to measure cardiac biomarkers. We will measure NT-proBNP and hs-cTnT at
baseline and follow-up years 1, 2, and 4 among ACCORD-BP trial participants who have blood stored in the
NHLBI Biorepository. The prognostic implications of baseline and longitudinal changes in NT-proBNP and hs-
cTnT for HF risk will be examined in a secondary analysis of the ACCORD-BP trial. Additionally, we will
evaluate whether NT-proBNP and hs-cTnT levels modify the treatment effects of intensive BP control. Finally,
we will test the hypothesis that intensive BP control can attenuate the expected rise in NT-proBNP and hs-
cTnT over follow-up. The proposed study will further our understanding of the clinical utility of cardiac
biomarker testing as part of a HF prevention strategy and provide preliminary data for designing a cardiac
biomarker-guided intensive BP control trial in T2D for HF prevention.

## Key facts

- **NIH application ID:** 10901969
- **Project number:** 5R21HL169708-02
- **Recipient organization:** UT SOUTHWESTERN MEDICAL CENTER
- **Principal Investigator:** Ambarish Pandey
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $124,885
- **Award type:** 5
- **Project period:** 2023-08-15 → 2026-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10901969

## Citation

> US National Institutes of Health, RePORTER application 10901969, Cardiac biomarkers, intensive blood pressure treatment and risk of adverse cardiovascular outcomes in type 2 diabetes, a secondary analysis of the ACCORD BP (5R21HL169708-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10901969. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*